z-logo
Premium
Correlative evidence that tumor cell‐derived caveolin‐1 mediates angiogenesis in meningiomas
Author(s) -
Barresi Valeria,
Cerasoli Serenella,
Tuccari Giovanni
Publication year - 2008
Publication title -
neuropathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 61
eISSN - 1440-1789
pISSN - 0919-6544
DOI - 10.1111/j.1440-1789.2008.00902.x
Subject(s) - immunohistochemistry , angiogenesis , endoglin , pathology , tumor progression , meningioma , caveolin 1 , medicine , biology , cancer research , cancer , cd34 , stem cell , genetics
Since it has recently been reported that caveolin‐1 (cav‐1) may favor the progression of prostatic and renal cancers by stimulating tumor neoangiogenesis, we thought it of interest to analyze the correlation between cav‐1 expression and tumor microvessel density (MVD) in meningiomas. In the present study we quantified cav‐1 expression by immunohistochemistry and used CD105 immunohistochemical staining to measure MVD. Sixty‐two formalin‐fixed, paraffin‐embedded, surgically resected meningiomas were submitted to the analysis. On the basis of cav‐1 immuno‐expression, cases were subdivided into meningiomas displaying a low ( n  = 34) and a high ( n  = 28) cav‐1 immuno‐expression, respectively. Mann–Whitney test showed that a significantly higher MVD was present in the cases with a high cav‐1 expression than in those with a low expression (mean 24.44 vs. 41.28 microvessels/mm 2 ) ( P  = 0.0001). Moreover, Spearman test revealed a significant positive correlation between cav‐1 rate of expression and MVD counts in the meningiomas of our series ( r  = 0.390; P  = 0.0023). Therefore, our study demonstrates the existence of an association between cav‐1 expression and neoangiogenesis in meningiomas, suggesting that cav‐1 may mediate the progression of these tumors by stimulating the angiogenic process. Besides, it is known that the progression of meningiomas is paralleled by an increase in MVD. The clarification of cav‐1 role in the neoangiogensis of meningiomas may open new insights about the possibility of novel therapeutic strategies in these neoplasias.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom